| This week's sponsor is FierceBiotech. | | | |
Today's Rundown Proclara nabs Merck Alzheimer’s R&D executive A new year, another new CEO at Syntimmune as Biogen, Sanofi veteran takes charge Boehringer more than doubles VC fund with boosted focus, reach Acceleron CMO to retire, but only after key data readout Scholar Rock scoops $47M to trial SMA drug Big Pharma vets bag $39M to drive I-O firm Elstar forward Microsoft, Google invest in genomics platform firm DNAnexus AstraZeneca, Myriad Genetics team to trial ovarian cancer drugs Featured Story | | | Wednesday, January 3, 2018 Proclara Biosciences (once NeuroPhage Pharmaceuticals) has poached Merck Research Labs veteran David Michelson, M.D., as its new chief medical officer. |
|
|
| This week's sponsor is Veeva. | | | [Webinar] Tufts eClinical Landscape Study: Q&A with Industry Experts
January 16, 2018 | 2pm ET / 11am PT
Hear expert analysis of the 2017 eClinical Landscape Survey, one of the largest, most in-depth surveys of clinical data management professionals that shows the impact of database build delays on trial timelines, as well as the projected increase of data source usage. Register Now |
Top Stories Wednesday, January 3, 2018 Just over a year ago Syntimmune announced Boehringer and Pfizer veteran David de Graaf, Ph.D., as its new CEO. Thirteen months later, he’s out the door, with a new leader at the helm. Wednesday, January 3, 2018 Boehringer Ingelheim is deepening its venture fund pockets from €100 million to a meatier €250 million ($300 million) as it looks to change up its investment strategy. Wednesday, January 3, 2018 After more than a decade in the role, Acceleron’s chief medical officer Matthew Sherman, M.D., has announced he will be leaving the company—but will hang on for pivotal results on its lead candidate luspatercept. Wednesday, January 3, 2018 Scholar Rock has raised $47 million to take its treatment for spinal muscular atrophy (SMA) into the clinic. The series C tees up Scholar Rock to find out whether its myostatin blocker can best the underwhelming performance of one-time rivals from companies including Novartis. Wednesday, January 3, 2018 Elstar Therapeutics has raised $39 million. The series A positions a management team with résumés dotted with senior posts at Serono, Eli Lilly and Novartis to advance multifunctional anticancer drugs toward human testing. Wednesday, January 3, 2018 Biopharma companies, medical research institutions and healthcare facilities have growing interest in getting more genomics data, and that has translated into new investments. A $58 million financing round DNAnexus completed is just one recent example. Wednesday, January 3, 2018 AstraZeneca and Myriad Genetics are partnering to identify women with advanced ovarian cancer who might benefit from treatments using Lynparza and Avastin as part of a phase 3 trial. Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Sponsored by: Deloitte Sourcing research externally seems to be the preferred path for biopharma companies to strengthen their R&D pipeline. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Sponsored by: Veeva Systems Read Deloitte Consulting's whitepaper on the value of a holistic RIM capability, covering the potential cost savings and revenue gains from doing RIM right. Presented By: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: DSM Biomedical Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases. Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. FierceBiotech Executive Breakfast: Get Good Science and the Money will Follow January 9, 2018 | San Francisco, CA Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA Drug Approval, Manufacturing Quality & Regulation 2018 | Online Field Service Medical February 26-28, 2018 | Hilton La Jolla, Torrey Pines, CA | 